- Acquisition extends global capabilities in AAV and plasmid gene therapy manufacturing for Ajinomoto, Co. Inc., diversifying and strengthening their current contract development and manufacturing services
- Positions Forge Biologics for accelerated long-term growth supporting gene and cell therapy clients worldwide
Atsena Therapeutics Receives FDA RMAT Designation for ATSN-101 Gene Therapy
RMAT designation recognizes the potential of ATSN-101 to address unmet medical needs for patients with LCA1
ATSN-101 has demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post-treatment in ongoing Phase I/II clinical trial
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
TORONTO and HAIFA, Israel — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for its ExoPTEN therapy, recognizing the potential of this groundbreaking regenerative therapy for acute spinal cord injury, a condition where effective treatments are limited. [Read more…]
World Organoid Research Day+ 2024
Attracts Leading Researchers & Technologies
Ticket sales help fund organoid research.
November 9th 2024, HERTFORDSHIRE, UNITED KINGDOM
After the success of this year’s 2023 event, World Organoid Research Day+ will be in person in Cambridge, UK, in 2024.
Avid Bioservices Completes Construction of World-Class Cell and Gene Therapy Development & Manufacturing Facility
Newly Launched CGMP Manufacturing Suites Undergoing Final Environmental Monitoring and Performance Qualification with Grand Opening Planned for January 2024
Completion of CGT Facility Brings Company’s Total Revenue Generating Capacity to up to Approximately $400 Million Annually
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 118
- Next Page »